Subgroup B recombinant human adenovirus vector, and methods for constructing and for using the same
AssigneeBeijing Bio-Targeting Therapeutics Technology Inc.
InventorsYaohe Wang, Guozhong Jiang, Hanshi Wong, Fengyu Cao, Nick Lemoine
Life of this patent
Estimating the term…
Abstract
A subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO: 1), which is constructed by a method including: substituting a 365 bp fragment containing an enhancer and a promoter of an upstream coding sequence of Ad5 E1A (SEQ ID NO: 2) for a corresponding region of a serotype Ad11 (SEQ ID NO: 3) of a subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO: 1).
Claims2
A subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO:
- 1), wherein the subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO:
- 1) is constructed by a method comprising substituting a 365 bp fragment comprising an enhancer and a promoter of an upstream coding sequence of Ad5 E1A (SEQ ID NO:
- 2) for a corresponding region of a serotype Ad11 (SEQ ID NO:
- 3) of a subgroup B human adenovirus vector by homologous recombination to construct the subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO:
- 1).
A method for treatment of tumor, the method comprising applying a subgroup B recombinant human adenovirus vector Ad11-5EP (SEQ ID NO:
- 1).
Dependencies are inferred from the claim text.